Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Kaner

Gastroenterology Cooper City, FL Medical Doctor

NPI 1366443947 CMS profile 107420

11011 Sheridan St, Suite 109, Cooper City, FL 33026

Open in the dashboard

General payments

$5,628

273 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Kaner of Cooper City, FL is reported in the CMS Open Payments database as having received $5,628 across 273 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,826 72
2024 General $1,023 48
2023 General $905 46
2022 General $842 41
2021 General $62 3
2020 General $266 20
2019 General $704 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Kaner
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jeffrey Kaner were reported at $1,826. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jeffrey Kaner Gastroenterology median Middle half National median
2019 $704 $417 $126–$1,100 $163
2020 $266 $224 $74–$624 $114
2021 $62 $352 $106–$1,054 $132
2022 $842 $448 $129–$1,270 $149
2023 $905 $533 $150–$1,390 $160
2024 $1,023 $605 $160–$1,606 $164
2025 $1,826 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,184 65 payments
  2. Janssen Biotech, Inc. $856 41 payments
  3. Genzyme Corporation $619 24 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $428 20 payments
  5. QOL Medical, LLC $248 16 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $243 10 payments
  7. Celgene Corporation $242 13 payments
  8. Intercept Pharmaceuticals, Inc. $236 11 payments
  9. Lilly USA, LLC $223 6 payments
  10. Gilead Sciences, Inc. $176 8 payments
  11. Other $1,173 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,628 273 payments
Products named General payments · program years 2019–2025
  1. STELARA $702 39 payments
  2. DUPIXENT $619 24 payments
  3. RINVOQ $475 23 payments
  4. TREMFYA $451 12 payments
  5. SIMPONI ARIA $370 14 payments
  6. SIMPONI $370 14 payments
  7. XIFAXAN $347 20 payments
  8. LINZESS $309 20 payments
  9. VIBERZI $247 15 payments
  10. ZEPOSIA $242 13 payments
  11. Other $3,356 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,857

Median for Gastroenterology: 569

Drug cost

$167,031

Median for Gastroenterology: $104,976

Branded share of claims

14.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 13 $52,437
Linzess Linaclotide Brand 47 $42,262
Mesalamine Generic 44 $17,133
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 70 $11,888
Omeprazole Generic 731 $8,586
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 53 $8,544
Pantoprazole Sodium Generic 366 $5,714
Dexlansoprazole Dr Dexlansoprazole Brand 18 $5,153
Ursodiol Generic 20 $4,261
Colesevelam Hcl Generic 12 $2,429

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$170,119

Of which drugs: $74,312

Medicare patients

477

Average age 74

Services billed

5,101

255 women, 222 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 45%
Chronic kidney disease 35%
Diabetes 32%
Depression 26%
Osteoporosis 26%
Cancer 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $165
  • Regeneron Healthcare Solutions, Inc. $26
$190 — —
STELARA
  • Janssen Biotech, Inc. $108
$108 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $79
$79 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $73
$73 — —
SKYRIZI
  • AbbVie, Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record